HLA-C and neoplasm: Engineered TCR therapy is similar in principle to CAR T cell therapy, but CAR recognizes tumor‐associated antigens independently of MHC presentation, thus freeing CAR T cell therapy from MHC constraints and enabling a more direct tumor‐killing effect.276